 SAN DIEGO, Oct. 12, 2021 PRNewswire -- Evofem Biosciences, Inc. NASDAQ: EVFM today announced that it has entered into a definitive agreement with Keystone Capital Partners Keystone Capital providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of 1,000.00 per share. The aggregate gross proceeds from this offering are expected to be an aggregate of approximately 10.0 million, before deducting estimated offering expenses payable by Evofem, and will close in two equal tranches with the second closing to occur on or about the 10th trading day following the initial closing. 